Covid. New Moderna booster vaccine also effective in Omicron subgroups

This was stated by the same company that is developing the updated version of its COVID-19 vaccine designed against the Omicron 1 variant. The latest tests have in fact highlighted a strong immune response against the other Omicron sub-variants, including B 4 and B 5. The company hopes for approval in the fall.

24 JUNE

(Reuters) -The updated version of the anti vaccine COVID-19 from Moderndesigned to attack the variant Omicron BA.1induced a strong immune response even against subgroups of Omicron BA.4 and BA.5, very contagious. The announcement comes from the US biotech itself.

The updated vaccine – which Moderna hopes will be approved as a booster in the fall – is a bivalent preparation that affects both the original 2020 strain of coronavirus, as well as the first version of Omicron, which circulated widely in the past winter.

“The antibody response is strong and powerful,” he said at a news conference Paul Burton, Moderna’s Chief Medical Officer. “This is probably a long-lasting effect and I think the booster or primary vaccination done with this updated vaccine could really represent a game changer in our fight against the SARS-COV-2 virus.”

Moderna also stated that the geometric mean titers of neutralizing antibodies BA.4 and BA.5 are comparable to the level of neutralizing antibodies to the Delta variant induced by the third dose of the original vaccine, which has already been shown in reality to be protective against infections.

The company plans to apply to regulatory authorities in the coming weeks to seek approval for the updated vaccine – called mRNA-1273.214 – for the next autumn season.

Source: Reuters

(Italian version of Quotidiano Sanità and Daily Health Industry)

June 24, 2022
© All rights reserved


Other articles in Studies and Analysis

image_1
image_2
image_3
image_4
image_5
image_6
Quotidianosanità.it

Online newspaper
health information.

QS Edizioni srl
VAT number 12298601001

Via Boncompagni, 16
00187 – Rome

Via Vittore Carpaccio, 18
00147 Rome (RM)

Site Manager

Cesare Fassari

Editorial director
Francesco Maria Avitto

President
Ernesto Rodriquez

Copyright 2013 © QS Edizioni srl. All rights reserved
– VAT number 12298601001
– registration in the ROC n. 23387
– registration at the Court of Rome n. 115/3013 of 22/05/2013

All rights reserved.
Privacy Policy


The article is in Italian

Tags: Covid Moderna booster vaccine effective Omicron subgroups

PREV Ilaria Capua: “Covid at the beginning of evolution, caution on variants”
NEXT Covid, RT returns to above one, cases increase by over 60%. Omicron 5 drives growth